MIRM - Mirum gains as FDA accepts label expansion of liver disease drug
2024-03-14 06:35:02 ET
Mirum Pharmaceuticals ( NASDAQ: MIRM ) shares climbed over 9% premarket on Thursday as the U.S. FDA cleared the company’s Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis (PFIC)....
Mirum gains as FDA accepts label expansion of liver disease drug